Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study

View Full Paper
Ask AI
Bookmark
Share

Authors

STSabrin TahriGAGloria AguilarMDMargaret Doyle

Discussion

Loading...

Member takes

Overview

Clinical trial shows improved progression-free survival with teclistamab and daratumumab in frail patients, suggesting enhanced treatment efficacy.

Key Points

  • Teclistamab and daratumumab combination improves progression-free survival in frail patients with newly diagnosed multiple myeloma when compared to traditional regimens.
  • The study aims to enroll 150 frail NDMM patients, evaluating safety, efficacy, and minimal residual disease negativity after treatment.
  • Randomized clinical trial assessing the safety and efficacy of teclistamab and talquetamab in two separate cohorts of patients with untreated myeloma.
  • Findings may enable optimized treatment protocols that incorporate dose modifications and supportive care to mitigate risks.

Cite This Study

Tahri et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236daa2https://doi.org/10.1182/blood-2025-4064
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a2025 · 12 citations
  2. 2A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)2025
  3. 3Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study2025 · 18 citations
  4. 4Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis2025
  5. 5Talquetamab outcomes from practice outside of clinical trials: The bital study2025